// App-Quantinova.ai

AB0356 : TARGETING THE RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLAST VIA CYCLIN DEPENDENT KINASE INHIBITION (TRAFIC): A PHASE 1B STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE OF SELICICLIB FOR REPURPOSING IN RHEUMATOID ARTHRITIS

Researchers

Presenter

  • A. Pratt

Principal Investigators

  • S. Siebert

  • M. Cole

  • D. Stocken

  • S. Kelly

  • M. Shaikh

  • A. Cranston

  • M. Morton

  • J. Walker

  • S. Frame

  • W. F. Ng

  • C. Buckley

  • I. Mcinnes

  • A. Filer

  • J. D. Isaacs

Medical Centers

  • Newcastle University, Translational and Clinical Research Institute, Newcastle Upon Tyne, United Kingdom

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Newcastle University, Population Health Sciences Institute, Newcastle Upon Tyne, United Kingdom

  • Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom

  • Department of Clinical Oncology, Barts Health NHS Trust, London, United Kingdom

  • Department of Gynaecological Oncology, James Cook University Hospital, Middlesborough, United Kingdom

  • Newcastle University Clinical Trials Unit, Newcastle upon Tyne, United Kingdom

  • Cyclacel, Dundee, United Kingdom

  • Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Seliciclib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved